News Releases

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Investor Alerts

Year All Years 2019 2018 2017 Keywords Go

Advanced Search

Search

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Mar 18, 2019

  Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
• Mar 14, 2019

  Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
• Mar 5, 2019

  Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
• Feb 22, 2019

  Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
• Feb 20, 2019

  Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation

  Topline data from ORCA-1 trial expected in mid-2019
• Dec 18, 2018

  Achieve Announces Update on Cytisinicline Clinical Development Program
• Nov 7, 2018

  Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
• Oct 31, 2018

  Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
• Oct 30, 2018

  Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation
• Oct 1, 2018

  Achieve Announces Pricing of $5.6 Million Registered Direct Offering

Show 5102550100 per page